<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148233</identifier>
<setSpec>0003-3170</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cost of abdominal aortic aneurysm treatment. Open repair compared to endovascular repair</dc:title>
<dc:description xml:lang="en">Objective: To compare costs of endovascular repair (EVAR) with open repair (OR) in abdominal aortic aneurysms. To determine the morbidity, mortality, and reintervention rates. Material and methods: A retrospective cohort study was conducted on patients with AAA that were treated during 2008-2009 with EVAR and OR, in order to obtain the total cost of each treatment. The study variables were extracted from the analytical accounting unit of our hospital. Such data consist of the cost of prosthesis, OR time, anaesthesia, blood products, intensive care unit, and length of hospital stay. Imaging tests and monitoring of patients after reintervention were also included. Complications, mortality (perioperative and follow-up) and reoperation rates, were recorded. Statistical analysis was performed using contingency tables according to a Cox model and the Student t test. Results: A total of 74 cases were found in the 2 year period of the study, of whom 40 patients were treated with OR, and 34 with EVAR. The mean cost was &#128;12,089.70 in OR and &#128;19,682.30 for EVAR (P&lt;.0001, 95% CI; 10,952.36&#150;13,488.11), with the differences due to the cost of the endoprosthesis accounting for 65.7% of the total. Mortality during follow-up was 20% in OR (8 cases), and 31.3% (10) in EVAR (p =.273). The reoperation rate was 20% (8) in OR, compared to 20.6% (7) in EVAR (p =.950). Conclusions: The endovascular treatment of AAA in our hospital is more expensive compared to OR. Although the current competitive market environment could possible put both treatments on the same level in the future (AU)</dc:description>
<dc:creator>Botas Velasco, M</dc:creator>
<dc:creator>Canto Peruyera, P del</dc:creator>
<dc:creator>Vaquero Lorenzo, F</dc:creator>
<dc:creator>Alvarez Fernández, LJ</dc:creator>
<dc:creator>Calvín Alvarez, P</dc:creator>
<dc:creator>Vallina Victorero, MJ</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Comparar los costes de la terapia endovascular (EVAR) con relación a la cirugía abierta (CA) del aneurisma de aorta abdominal (AAA). Conocer la morbimortalidad y tasa de reintervención. Material y métodos: Realizamos un estudio de cohorte retrospectivo recogiendo los pacientes con AAA tratados entre 2008 y 2009 mediante EVAR y CA. Se halla el coste total de cada tratamiento mediante datos extraídos de la gestión analítica de nuestro centro, a partir del coste de la prótesis, tiempo de quirófano y anestesia, uso de hemoderivados, estancia en Unidad de Reanimación y estancia media. Se incluyen también costes durante el seguimiento por reintervención y pruebas de imagen. Recogimos complicaciones, mortalidad (perioperatoria y durante el seguimiento) y tasa de reintervención. El análisis estadístico se realizó mediante tablas de contingencia según modelo de Cox y prueba t de Student. Resultados: Recogimos 74 casos en 2 años, 40 tratados mediante CA y 34 mediante EVAR con un seguimiento medio de 46,84 meses. La media del coste total fue 12.089,70 &#128; para la CA y 19.682,30 &#128; para EVAR (p &lt; 0,0001; IC 95%: 10.952,36-13.488,11), diferencias debidas al coste de la endoprótesis que supuso el 65,7% del total. La mortalidad durante el seguimiento fue del 20% en CA (8 casos) y 31,3% (10) en EVAR (p = 0,273). La tasa de reintervención fue del 20% (8) en CA frente al 20,6% (7) en EVAR (p = 0,950). Conclusiones: El tratamiento endovascular de los AAA en nuestro centro hospitalario es más caro en comparación concon la CA. La competitividad de mercado entre los diferentes dispositivos comerciales podría equiparar en un futuro ambos tratamientos (AU)</dc:description>
<dc:source>Angiologia;68(1): 20-25, ene.-feb. 2016. tab, graf</dc:source>
<dc:identifier>ibc-148233</dc:identifier>
<dc:title xml:lang="es">Coste del tratamiento del aneurisma de aorta abdominal: cirugía abierta frente a tratamiento endovascular</dc:title>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d1017^s29166</dc:subject>
<dc:subject>^d30829^s22080</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d30769</dc:subject>
<dc:subject>^d54238^s22018</dc:subject>
<dc:subject>^d28418</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d30829^s29166</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d12508^s22066</dc:subject>
<dc:subject>^d30829^s22018</dc:subject>
<dc:subject>^d12508^s22045</dc:subject>
<dc:subject>^d12508^s22018</dc:subject>
<dc:subject>^d50303</dc:subject>
<dc:subject>^d1017^s22009</dc:subject>
<dc:subject>^d54238^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201602</dc:date>
</metadata>
</record>
</ibecs-document>
